News

In honor of March being Amyloidosis Awareness Month, the Amyloidosis Foundation is hosting its annual Light the Night campaign.

Gene silencing and antifibril therapy could stop disease progression and eliminate amyloid deposits in patients with ATTR-CM.

A new artificial intelligence-based tool may improve quick and accurate ATTR-CM diagnosis using scintigraphy images.

Sodium-glucose cotransporter 2 inhibitors may improve clinical outcomes and health care usage in patients with ATTR-CM.

ATTR-CM is being diagnosed more frequently because of improved awareness and diagnostic tools, making it more common than previously thought.

The European Commission approved acoramidis to treat adults with wild-type or variant ATTR-CM in the European Union.

The barriers to treatment of ATTR-CM included lack of affordability, delayed diagnosis and underrepresented populations in clinical trials.

A case of transthyretin amyloid cardiomyopathy (ATTR-CM) presented with symptoms generally associated with a different heart condition.

SLGT2is improved long-term outcomes in patients with ATTR-CM, a literature review found.

Analysis of data from the trial suggested that outpatient heart failure should be an endpoint in future clinical studies for ATTR-CM.